Comparative Pharmacology
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus ALEVE D SINUS COLD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus ALEVE D SINUS COLD.
ADVIL MIGRAINE LIQUI-GELS vs ALEVE-D SINUS & COLD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
400 mg (two 200 mg Liqui-Gels) orally every 6 to 8 hours as needed; maximum 1200 mg per day.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.8–3.5 hours). In clinical context, this short half-life supports dosing every 4–6 hours for acute migraine treatment, but drug effects may persist beyond this due to slow dissociation from COX enzymes.
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 90% of an administered dose, with about 10% excreted in feces via bile. Less than 1% is excreted unchanged in urine; the remainder as conjugates and oxidative metabolites.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Category C
Category C
NSAID
NSAID/Decongestant Combination